Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)

Standard BioTools Inc LAB

Technology Scientific & Technical Instruments

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

NDAQ:LAB - Post by User

Standard BioTools Inc

<< Previous

Bullboard Posts

Next >>

Post by Humaniston Sep 21, 2020 1:32pm

86 Views

Post# 31591800

FLDM GETS $20 PRICE TARGET & MAJOR CONFIDENCE FROM CITRON

Fluidigm pops further on Citron confidence

Sep. 18, 2020 2:50 PM ET |About: Fluidigm Corporation (FLDM)|By: Kim Khan, SA News Editor

Fluidigm (FLDM, +13%) is adding to already strong daily gains as Citron Research reiterates its long on the stock with a price target more than double current levels.

"CDC has just opened the floodgates for testing," Citron tweets. "$FLDM has only FDA approved saliva-based test as effective as nasal swabs. $FLDM announced 2 days ago new lab customer running 3K tests per day. Expect more customers to be announced shortly."

Its price target is $20. The stock stands at about $8.20 currently.

The FDA OK'd use of the Fluidigm's saliva-based test at the end of August.

Shares are up more than 200% in the last six months, but off more than 12% in the past month.